Dosimetric Evaluation of an Abscopal Response in an Oligometastatic Melanoma Patient Receiving Pembrolizumab and Stereotactic Body Radiation (SBRT) at the Same Time

Abstract

Recently, preclinical and clinical evidence has shown that a synergy may exist between radiation and immune check-point therapies such as pembrolizumab. Radiation has been shown to activate the immune system, and in combination with immunotherapy may lead to systemic anti-tumor responses. However, the exact dose regimens needed to induce synergistic responses are unclear. Here, we report a dosimetric characterization of a patient treated with stereotactic radiation in combination with immune check-point therapy.